Get the Stockscreener App
26.30
0.69%
0.18
Pre-market:
26.25
-0.05
-0.19%
Ultragenyx Pharmaceutical Inc stock is traded at $26.30, with a volume of 1.71M.
It is up +0.69% in the last 24 hours and up +12.88% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$26.12
Open:
$26.45
24h Volume:
1.71M
Relative Volume:
0.85
Market Cap:
$2.59B
Revenue:
$672.72M
Net Income/Loss:
$-575.44M
P/E Ratio:
-4.5064
EPS:
-5.8361
Net Cash Flow:
$-487.00M
1W Performance:
+6.01%
1M Performance:
+12.88%
6M Performance:
-20.90%
1Y Performance:
-25.09%
1-Day Range:
$26.21
$27.42
1-Week Range:
$24.23
$27.42
52-Week Range:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
26.30 | 2.57B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com Nigeria
Number of shareholders of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Number of shareholders of Ultragenyx Pharmaceutical, Inc. – FWB:UP0 - TradingView
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses? - Yahoo Finance
RARE SEC FilingsUltragenyx Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard Group Inc. Buys 131,087 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Ultragenyx Pharmaceutical (RARE) Is Up 5.8% After Reaffirming 2026 Outlook Despite Wider Losses – What's Changed - Sahm
Rare Q1 loss wider than expected, sales down Y/Y on seasonal effect - msn.com
RARE Maintained by Wedbush -- Price Target Lowered to $26 - GuruFocus
RARE Maintained by Guggenheim -- Price Target Lowered to $43 - GuruFocus
Guggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
Ultragenyx to Present at Bank of America Healthcare Conference on May 13, 2026 - geneonline.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript - Insider Monkey
Rare disease families find roadmap to drug development at bootcamps - CNBC
Ultragenyx Pharmaceutical (RARE) Heavy Q1 EPS Loss Tests Bulls Profitability Timeline Narrative - Sahm
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk - TipRanks
Ultragenyx Pharmaceutical Inc. 2024 SEC Filing: Financial Information, Forward-Looking Statements, and Market Risks - Minichart
Ultragenyx investors can watch CFO at Bank of America panel May 12 - Stock Titan
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference - The Manila Times
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com India
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares By Investing.com - Investing.com South Africa
Ultragenyx (NASDAQ: RARE) CMO sells shares to cover RSU taxes - Stock Titan
Ultragenyx outlines $730M-$760M 2026 revenue as it targets two gene therapy PDUFAs in August and September - MSN
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan
Wedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Privium Fund Management B.V. - MarketBeat
Ultragenyx Pharmaceutical Q1 Loss Widens, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS - MarketBeat
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts By Investing.com - Investing.com Canada
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts - Investing.com
Ultragenyx (NASDAQ: RARE) Q1 loss widens as R&D and restructuring costs rise - Stock Titan
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript - Benzinga
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ultragenyx Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ULTRAGENYX PHARMACEUTICAL ($RARE) Releases Q1 2026 Earnings - Quiver Quantitative
Ultragenyx: Q1 Earnings Snapshot - marketscreener.com
Gene therapy reviews and Q1 2026 results at Ultragenyx (RARE) - Stock Titan
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q1 Revenue $136.0M, Vs. FactSet Est of $158.4M - Moomoo
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.70%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):